HomeNDC LookupIngredientsCiclopirox Olamine › 68462-0297-17
Ciclopirox Olamine 7.7 mg/g Cream, 15 g — NDC 68462-0297-17 package photo

Ciclopirox Olamine 7.7 mg/g Cream, 15 g

by Glenmark Pharmaceuticals Inc., USA · 15 g in 1 CARTON (68462-297-17)
NDC 68462-0297-17
🏷️ FDA NDC (as labeled) 68462-297-17 billing pads the product segment with a zero
This package
Contains15 g Cost per g$0.2171 NADAC Per package$3.26 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.4038/unit · Part D plans $0.3074/unit — full pricing hub ↓
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 68462-297-17
Product NDC 68462-297
11-digit billing NDC 68462029717
NCPDP billing unit GM — per gram (weight)
RxCUI 309289
UNII 50MD4SB4AP
UPC 0368462297353
Application # ANDA090273
SPL Set ID 7385cf42-9f80-4542-8e0f-a0228aa9b43a
Mechanism of action Protein Synthesis Inhibitors
Physiologic effect Decreased DNA Replication; Decreased Protein Synthesis; Decreased RNA Replication
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-11-13
Route TOPICAL
Dosage form CREAM
Substance CICLOPIROX OLAMINE
GPI-14 90150030103705
GPI class Ciclopirox Olamine
GCN Seq No 040971
GCN 94677
HICL code 003203
Ingredient (HICL) Ciclopirox Olamine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.20
AHFS class Hydroxypyridones (Skin, Mucous Membrane)
FDB label name CICLOPIROX 0.77% CREAM
FDB brand name Ciclopirox
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 68462-297-17 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 68462-0297-17. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Other antifungals for topical use class.

Drug family (ATC) Other antifungals for topical use, Other antiinfectives and antiseptics
How it works Protein Synthesis Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerGlenmark Pharmaceuticals Inc., USA
Application holderGLENMARK PHARMACEUTICALS INC USA
FDA applicationANDA090273 (ANDA)
Labeler code68462
First marketedNov 2009
Product typeHuman Prescription Drug
Portfolio343 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CICLOPIROX 0.77% CREAM Ingredient Ciclopirox Olamine
📖 What it is MedlinePlus · NLM

Ciclopirox topical solution is used along with regular nail trimming to treat fungal infections of the fingernails and toenails (an infection that may cause nail discoloration, splitting and pain). Ciclopirox is in a class of medications called antifungals. It works by stopping the growth of nail fungus.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Fungal nail infections are slow to clear, and Ciclodan nail lacquer is no exception. In clinical studies, treatment lasted up to 48 weeks. Only a small percentage of patients achie...
  • How long does it take for the nail lacquer to work?
  • No — that's actually one of the most important things to get right. You apply Ciclodan once a day and leave it on. Each new coat goes right on top of the previous one. After seven...
  • Do I need to remove the nail lacquer every night before I apply a new coat?
📖 Read our full Ciclopirox Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 33X04XA5AT
    Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
  • UNII N6K5787QVP
    Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
  • UNII V42034O9PU
    A fatty alcohol derived from coconut or palm oil. It serves as an emulsifier and thickener to help blend oil and water in creams or lotions, and improves the product's texture and consistency.
  • UNII 461N1O614Y
    A synthetic oily liquid used as an emollient and solvent in medications. It helps dissolve active ingredients and improves how the medicine spreads or absorbs through the skin.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII NVZ4I0H58X
    A waxy substance made from sorbitol and stearic acid. It acts as an emulsifier and stabilizer, helping keep oil and water mixed together and preventing separation in the medicine.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.217 $3.26 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.4038 $6.06 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3074 $4.61 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.308 $0.206
▼ Down 19% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ciclopirox olamine 7.7 mg/g 45802-0138-11 Padagis 1 tube $0.173 AB Availability likely save 20%
Ciclopirox Olamine 7.7 mg/g 00713-0638-15 Cosette 1 tube $0.217 AB Availability likely
Ciclopirox Olamine 7.7 mg/g 51672-1318-01 Sun 1 tube $0.217 AB Availability likely
Ciclopirox Olamine 7.7 mg/gthis 68462-0297-17 Glenmark 15 g $0.217 AB Availability likely
Ciclopirox Olamine 7.7 mg/g 63629-8624-01 Bryant 1 tube AB FDA listed
Ciclopirox Olamine 7.7 mg/g 63629-8625-01 Bryant 1 tube AB FDA listed
Ciclopirox olamine 7.7 mg/g 63629-8626-01 Bryant 1 tube AB FDA listed
Ciclopirox olamine 7.7 mg/g 71335-2865-01 Bryant 1 tube AB FDA listed
Ciclopirox Olamine 7.7 mg/g 72162-1397-02 Bryant 1 tube AB FDA listed
Ciclopirox Olamine 7.7 mg/g 80425-0225-01 Advanced 30 g AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2009
On the market since
Nov 2009
📍
2026
Currently FDA-listed
17 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 68462-0297-17, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.6K
Units reimbursed last 4 qtrs
84.9K
Gross reimbursed last 4 qtrs
$34.3K
Avg / prescription
$13.23
Avg / unit
$0.4038
Latest quarter Q4 2025
471Rx
Medicaid pays / g
$0.4038
gross reimbursed
vs
NADAC / g
$0.2171
acquisition cost
=
Spread
+$0.1867
+86% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
44% FFS 56% MCO
Fee-for-service · 1,148 Rx Managed care · 1,442 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 2,955 units · 37.8 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 2,475 units · 24.7 per 100k residents MI New York: 17,310 units · 88.4 per 100k residents NY Vermont: no data reported VT New Hampshire: 570 units · 40.7 per 100k residents NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 2,145 units · 66.9 per 100k residents IA Illinois: no data reported IL Indiana: 930 units · 13.6 per 100k residents IN Ohio: 6,915 units · 58.7 per 100k residents OH Pennsylvania: 6,900 units · 53.2 per 100k residents PA New Jersey: 6,405 units · 68.9 per 100k residents NJ Massachusetts: no data reported MA California: 13,935 units · 35.8 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 3,705 units · 59.8 per 100k residents MO Kentucky: 405 units · 8.9 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 2,100 units · 34.0 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 3,240 units · 153 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 960 units · 13.5 per 100k residents TN North Carolina: 3,855 units · 35.6 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: 285 units · 5.6 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 3,645 units · 11.9 per 100k residents TX Florida: 6,120 units · 27.1 per 100k residents FL
Units reimbursed · per 100k residents
5.6153
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Mexico 153 /100k
2 New York 88.4 /100k
3 New Jersey 68.9 /100k
4 Iowa 66.9 /100k
5 Missouri 59.8 /100k
6 Ohio 58.7 /100k
7 Pennsylvania 53.2 /100k
8 New Hampshire 40.7 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
90 gs68462-0297-92 20,797 Rx · $347,094
30 gs68462-0297-35 7,358 Rx · $107,704
15 gs this page68462-0297-17 2,590 Rx · $34,265
Drug total (last 4 qtrs): 30,745 Rx · 1,783,526 units · $489,063 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ciclopirox (matched by generic name) — the program that covers self-administered drugs. 6 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ciclopirox. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.34M
Claims incl. refills
125.3K
Beneficiaries
93.6K
Spend / beneficiary
$35.64
Spend / claim
$26.62
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for CICLOPIROX OLAMINE — the ingredient across all brands.

Top reported reactions

Device Dislocation78
Device Malfunction78
Rash25
Fatigue22
Pruritus21
Condition Aggravated17
Pain17

Age at onset

Adult50
Elderly25

Reporter sex

470 reports
Male · 61%
Female · 39%
Unknown · 1%

Serious outcomes

Hospitalization200
Life-threatening37
Disabling26
Death15
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 63 14
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
68462-0297-17 You're viewing this 15 g in 1 CARTON (68462-297-17) $0.2171 / g $3.26 2009-11-13 Active
68462-0297-35 30 g in 1 CARTON (68462-297-35) $0.1729 / g $5.19 2009-11-13 Active
68462-0297-92 90 g in 1 CARTON (68462-297-92) $0.1045 / g $9.40 2009-11-13 Active

You're viewing the smallest of 3 pack sizes for this product.

Per g, this pack runs about 108% above the cheapest pack (90 g, $0.1045 vs $0.2171 NADAC).

This pack accounts for about 8.4% of this product's recent Medicaid fills; most go to the 90 gs pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 68462-0297-17?
NDC 68462-0297-17 contains 15 g — 15 g in 1 carton.
What is the difference between NDC 68462-0297-17 and NDC 68462-0297-35?
Both are Ciclopirox Olamine 7.7 mg/g Cream — the drug itself is identical. NDC 68462-0297-17 is the 15 g package, while NDC 68462-0297-35 is the 30 g package. Per-g NADAC also differs: $0.2171 here vs $0.1729 for the 30 g pack.
What NDC number is used to bill for this package of Ciclopirox Olamine 7.7 mg/g Cream?
Bill NDC 68462-0297-17 — the 11-digit billing format is 68462029717. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 52 words

INDICATIONS AND USAGE Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) versicolor due to Malassezia furfur.

⏱️ Dosage and Administration 75 words

DOSAGE AND ADMINISTRATION Gently massage ciclopirox olamine cream into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with ciclopirox olamine cream, the diagnosis should be redetermined.

Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

Contraindications 17 words

CONTRAINDICATIONS Ciclopirox olamine cream is contraindicated in individuals who have shown hypersensitivity to any of its components.

⚠️ Warnings 15 words

WARNINGS Ciclopirox olamine cream is not for ophthalmic use. Keep out of reach of children.

🤒 Adverse Reactions 75 words

ADVERSE REACTIONS In all controlled clinical studies with 514 patients using ciclopirox olamine cream and in 296 patients using the vehicle cream, the incidence of adverse reactions was low. This included pruritus at the site of application in one patient and worsening of the clinical signs and symptoms in another patient using ciclopirox olamine cream and burning in one patient and worsening of the clinical signs and symptoms in another patient using the vehicle cream.

🤰 Pregnancy 174 words

Pregnancy Teratogenic Effects: Pregnancy Category B There are no adequate or well-controlled studies in pregnant women. Therefore, ciclopirox cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys.

Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 11, 37, 51 and 24 times the maximum recommended human dose based on body surface area comparisons, respectively). Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400.

Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 27 and 49 times the maximum recommended human dose based on body surface area comparisons, respectively).

🧒 Pediatric Use 18 words

Pediatric Use Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

🧬 Clinical Pharmacology ~1 min read

CLINICAL PHARMACOLOGY Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell. Pharmacokinetics Pharmacokinetic studies in men with tagged ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm 2 on the back followed by occlusion for 6 hours.

The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

Penetration studies in human cadaverous skin from the back, with ciclopirox olamine cream with tagged ciclopirox showed the presence of 0.8 to 1.6% of the dose in the stratum corneum 1.5 to 6 hours after application. The levels in the dermis were still 10 to 15 times above the minimum inhibitory concentrations. Autoradiographic studies with human cadaverous skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.

Draize Human Sensitization Assay, 21-Day Cumulative Irritancy study, Phototoxicity study, and Photo-Draize study conducted in a total of 142 healthy male subjects showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity, and no photo-contact sensitization due to ciclopirox olamine cream.

🧬 Mechanism of Action 42 words

Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

📦 How Supplied / Storage and Handling 24 words

HOW SUPPLIED Ciclopirox olamine cream USP, 0.77% is supplied in 15 grams (NDC 68462-297-17), 30 grams (NDC 68462-297-35) and 90 grams (NDC 68462-297-92) tubes.

📦 Storage and Handling 13 words

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

📋 Description 95 words

DESCRIPTION Ciclopirox olamine cream, USP, 0.77% is for topical use. Each gram of ciclopirox olamine cream, USP contains 7.70 mg of ciclopirox (as ciclopirox olamine USP) in a water miscible vanishing cream base consisting of benzyl alcohol (1%) as preservative, cetyl alcohol, lactic acid, light mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate and stearyl alcohol. Ciclopirox olamine cream, USP contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine USP).

The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridone, 2 -aminoethanol salt. The CAS Registry Number is 41621-49-2. The chemical structure is: structure

💬 Information for Patients 70 words

Information for Patients The patient should be told to: 1. Use the medication for the full treatment time even though symptoms may have improved and notify the physician if there is no improvement after four weeks. 2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible sensitization. 3. Avoid the use of occlusive wrappings or dressings.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.